ICU Medical (ICUI) Q3 2026 Earnings Call Transcript
ICU Medical (ICUI) reported Q3 2026 adjusted EPS of $2.44, up 20% YoY, with adjusted EBITDA at $114M. Revenue growth was driven by consumables (+5%) and IV systems (+11%), while Vital Care declined (-10%). The company expects full-year EBITDA and EPS to be at the higher end of previous guidance.
How this was made
The 30-second read
Why it matters
The disclosed numbers and guidance are new information that can move the stock.
Market read
First report of Q3 earnings with improved margins and higher‑end guidance, offering a clear trading catalyst.
What to watch
Potential headwinds from international logistics consolidation and OEM wind‑down could dampen future growth.
Background
ICU Medical provided its Q3 2026 earnings call transcript, highlighting margin improvement, cash flow generation, debt reduction and guidance guidance.
Ticker impact
Q3 2026 earnings call disclosed adjusted gross margin of 42%, adjusted EPS $2.44, free cash flow $83M and raised full‑year guidance to the higher end of the range.
likely upside as the market prices in better margins and higher guidance
Margins beat expectations, cash flow strong, debt reduction and guidance at the top of range all support a bullish reaction.
Market effects
Healthcare equipment sector may see modest lift from ICU Medical's strong margins and guidance.
U.S. market participants focused on the earnings beat; limited regional spillover.
Limited global impact beyond U.S. healthcare investors.
Counterpoint
If the guidance range is already priced in, the stock could face disappointment on any shortfall.
Key entities
- companyICU Medical
U.S. medical device maker (ticker ICUI) reporting Q3 2026 results.
